Multicenter Evaluation of Ceftazidime-Avibactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa on the Vitek 2 System-Reference-Cited by-同舟云学术

Multicenter Evaluation of Ceftazidime-Avibactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa on the Vitek 2 System

Published:2021-02-18 Issue:3 Volume:59 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Humphries Romney¹^ORCID,Campeau Shelley¹,Davis Thomas E.²,Nagaro Kristin J.²,LaBombardi Vincent J.³,Franklin Simone⁴,Heimbach Lisa⁵,Dwivedi Hari P.⁴^ORCID

Affiliation:

1. UCLA Health System, Los Angeles, California, USA

2. Indiana University School of Medicine, Indianapolis, Indiana, USA

3. NewYork-Presbyterian Queens, Flushing, New York, USA

4. bioMérieux, Inc., Hazelwood, Missouri, USA

5. bioMérieux, Inc., Durham, North Carolina, USA

Abstract

In this multisite study, Vitek 2 AST-Gram-Negative Ceftazidime/Avibactam test results for 1,073 isolates (866 Enterobacterales and 207 Pseudomonas aeruginosa ) were compared to the Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BMD) reference method. The results were analyzed for essential agreement (EA), category agreement (CA), major error rates, and very major error rates following FDA/ISO performance criteria using the FDA-recognized CLSI/EUCAST breakpoints (sensitive [S], ≤8/4 μg/ml; resistant [R], ≥16/4 μg/ml).

Funder

bioMerieux, Inc.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01870-20

Reference17 articles.

1. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms

2. CDC. 2019. Antibiotic resistance threats in the United States, 2019. CDC, Atlanta, GA.

3. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections

4. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

5. National Institutes of Health US National Library of Medicine. 2019. AVYCAZ- ceftazidime avibactam powder for solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam;Microbiology Spectrum;2024-06-04

2. DP1, a multifaceted synthetic peptide: Mechanism of action, activity and clinical potential;Life Sciences;2024-03

3. Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion;Antibiotics;2023-10-09

4. Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa;Microbiology Spectrum;2023-04-13

5. Comparative Experimental Investigation of Biodegradable Antimicrobial Polymer-Based Composite Produced by 3D Printing Technology Enriched with Metallic Particles;International Journal of Molecular Sciences;2022-09-23